Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans
Executive Summary
US FDA rescinds breakthrough designations for Tonix’ PTSD therapy Tonyma and Trevena’s novel pain drug Olinvo after clinical trial disappointments – and after identifying other regulatory pathways to market.